Immuron Ltd ADR (IMRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immuron Ltd ADR (IMRN) has a cash flow conversion efficiency ratio of -0.267x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.14 Million) by net assets ($8.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immuron Ltd ADR - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Immuron Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Immuron Ltd ADR total liabilities for a breakdown of total debt and financial obligations.
Immuron Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immuron Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BAWAT WATER TECHNOLOGIES
F:M5W
|
N/A |
|
Biomerica Inc
NASDAQ:BMRA
|
-0.223x |
|
Rolling Optics Holding AB (publ)
ST:RO
|
-0.033x |
|
Empiric Student Property Plc
LSE:ESP
|
-0.009x |
|
Sewon E&C
KO:091090
|
-0.052x |
|
AHB Holdings Bhd
KLSE:7315
|
-0.391x |
|
Diriteks Dirilis Tekstil Sanayi ve Ticaret AS
IS:DIRIT
|
-0.030x |
|
Ansal Properties & Infrastructure Limited
NSE:ANSALAPI
|
-0.110x |
Annual Cash Flow Conversion Efficiency for Immuron Ltd ADR (2001–2025)
The table below shows the annual cash flow conversion efficiency of Immuron Ltd ADR from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Immuron Ltd ADR worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $8.03 Million | $-6.14 Million | -0.764x | -65.15% |
| 2024-06-30 | $12.71 Million | $-5.88 Million | -0.463x | -264.71% |
| 2023-06-30 | $19.62 Million | $-2.49 Million | -0.127x | +6.13% |
| 2022-06-30 | $23.18 Million | $-3.13 Million | -0.135x | -14.89% |
| 2021-06-30 | $25.90 Million | $-3.05 Million | -0.118x | +79.02% |
| 2020-06-30 | $5.64 Million | $-3.16 Million | -0.561x | -220.48% |
| 2019-06-30 | $7.35 Million | $-1.29 Million | -0.175x | +57.86% |
| 2018-06-30 | $8.44 Million | $-3.50 Million | -0.415x | +61.17% |
| 2017-06-30 | $6.57 Million | $-7.03 Million | -1.069x | -40.75% |
| 2016-06-30 | $4.94 Million | $-3.75 Million | -0.760x | -20.99% |
| 2015-06-30 | $4.81 Million | $-3.02 Million | -0.628x | -60.80% |
| 2014-06-30 | $6.79 Million | $-2.65 Million | -0.391x | +97.23% |
| 2013-06-30 | $144.99K | $-2.05 Million | -14.108x | -1074.35% |
| 2012-06-30 | $2.05 Million | $-2.46 Million | -1.201x | -5.67% |
| 2011-06-30 | $1.73 Million | $-1.97 Million | -1.137x | -69.19% |
| 2010-06-30 | $3.36 Million | $-2.26 Million | -0.672x | -105.99% |
| 2009-06-30 | $-184.87K | $-2.07 Million | 11.209x | +699.89% |
| 2008-06-30 | $1.11 Million | $-2.07 Million | -1.868x | -23.80% |
| 2007-06-30 | $1.98 Million | $-2.99 Million | -1.509x | -181.71% |
| 2006-06-30 | $5.24 Million | $-2.81 Million | -0.536x | -112.46% |
| 2005-06-30 | $6.96 Million | $-1.76 Million | -0.252x | +16.78% |
| 2004-06-30 | $4.08 Million | $-1.24 Million | -0.303x | +0.21% |
| 2002-06-30 | $6.32 Million | $-1.92 Million | -0.304x | -36.77% |
| 2001-06-30 | $7.48 Million | $-1.66 Million | -0.222x | -- |
About Immuron Ltd ADR
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more